ERBB2 and interstitial lung disease: To our knowledge, this study provides the first and most detailed evaluation of the pre-treatment prevalence, and subsequent incidence of ILD, along with associated risk factors, in a real-world, and thus clinically diverse, patient population with mBC who received HER2-directed therapies within US community health systems.